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Abstract 
This review summarizes the (patho)-physiological effects of ventilation with high FiO2 (0.8–1.0), with a special focus on 
the most recent clinical evidence on its use for the management of circulatory shock and during medical emergen-
cies. Hyperoxia is a cornerstone of the acute management of circulatory shock, a concept which is based on compel-
ling experimental evidence that compensating the imbalance between O2 supply and requirements (i.e., the oxygen 
dept) is crucial for survival, at least after trauma. On the other hand, “oxygen toxicity” due to the increased formation 
of reactive oxygen species limits its use, because it may cause serious deleterious side effects, especially in condi-
tions of ischemia/reperfusion. While these effects are particularly pronounced during long-term administration, i.e., 
beyond 12–24 h, several retrospective studies suggest that even hyperoxemia of shorter duration is also associated 
with increased mortality and morbidity. In fact, albeit the clinical evidence from prospective studies is surprisingly 
scarce, a recent meta-analysis suggests that hyperoxia is associated with increased mortality at least in patients after 
cardiac arrest, stroke, and traumatic brain injury. Most of these data, however, originate from heterogenous, observa-
tional studies with inconsistent results, and therefore, there is a need for the results from the large scale, randomized, 
controlled clinical trials on the use of hyperoxia, which can be anticipated within the next 2–3 years. Consequently, 
until then, “conservative” O2 therapy, i.e., targeting an arterial hemoglobin O2 saturation of 88–95 % as suggested by 
the guidelines of the ARDS Network and the Surviving Sepsis Campaign, represents the treatment of choice to avoid 
exposure to both hypoxemia and excess hyperoxemia.
© 2015 Hafner et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
The “double-edged sword” character of molecular oxygen 
(O2) is well established and has been a matter of debate 
since its discovery at the end of the eighteenth century. 
On the one hand, O2 plays a crucial role during adeno-
sine triphosphate (ATP) synthesis [1]. On the other hand, 
its chemical characteristics lead to strong oxidizing 
properties, capable of damaging any biological molecule 
[1], and thereby defining the paradigm of oxygen toxic-
ity. This phenomenon is due to the formation of reac-
tive oxygen species (ROS), its magnitude being directly 
correlated to the level of the O2 partial pressure [2, 3]. 
Moreover, during mitochondrial respiration, 1–3 % of O2 
consumption leads to ROS formation [3]. Like O2, ROS 
also exert Janus-headed properties: while being of impor-
tance for host defense and signaling cascades, their toxic 
effects are well known [4].
Circulatory shock is defined as “…an imbalance 
between O2 supply and requirements…” [5], and conse-
quently, a logical therapeutic strategy is to increase the 
inspired O2 concentration (FiO2). The recommenda-
tion that the administration of oxygen should be started 
immediately to increase O2 delivery [6] has been known 
for a long time as a part of the “V” (“ventilate”) com-
ponent of the “VIP” (“ventilate–infuse–pump”) rule 
for shock resuscitation [6]. Due to this, supplemental 
O2 was an integral part of all resuscitation protocols of 
the recently published Protocolized Care for Early Sep-
tic Shock (ProCESS) trial [7]. However, literature data 
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concerning the high-dose administration of O2 are still 
highly controversial [8–14]. Moreover, hyperoxia (i.e., 
an increased FiO2) must be distinguished from hyper-
oxemia (i.e. increased arterial O2 partial pressure): in 
patients with severe Acute Respiratory Distress Syn-
drome (ARDS), hyperoxia may be mandatory to avoid 
hypoxemia with the least mechanical ventilation-induced 
hemodynamic compromise and/or ventilator-induced 
damage to the lung possible. This is nicely demonstrated 
by the results of the ARDSNetwork trial on low tidal 
volume ventilation: the FiO2 was significantly higher in 
the group with lower tidal volumes that ultimately had 
improved survival [15]. Figure 1 [16] summarizes the key 
pro and con arguments concerning the use of O2 therapy 
during shock states. Data from prospective, controlled, 
randomized trials on the use of therapeutic hyperoxia, 
however, are surprisingly scarce. Consequently, given the 
possible deleterious side effects of hyperoxia, the current 
guidelines of the ARDSNetwork and the Surviving Sepsis 
Campaign recommend using an FiO2 that allows achiev-
ing an arterial hemoglobin O2 saturation of 88–95  % at 
airway plateau pressures and PEEP levels of <30 and 
5–20 cmH2O, respectively [15, 17]. The present review 
will, therefore, discuss the role of ventilation with high 
FiO2 (0.8–1.0) during circulatory shock, during medical 
emergencies and in the peri-operative period; the first 
part will briefly summarize the (patho)-physiological 
effects of hyperoxia, the second part will review its use in 
the context of important pathological entities, with a par-
ticular focus on the most recent clinical evidence.
(Patho)physiology of hyperoxia: pulmonary, 
vascular, metabolic, and cerebral effects
Blood O2 content
According to textbook physiology, increasing the FiO2 
from 0.21 (i.e., air) to 1.0 (i.e., 100  % O2) will moder-
ately affect total blood O2 content under conditions of 
normal cardiopulmonary function: at normal pH and 
Fig. 1 Beneficial (green arrows) and deleterious (red arrows) effects of hyperoxia, i.e., breathing pure oxygen, during circulatory shock and/or in 
medical emergencies. FiO2 fraction of inspired oxygen, PO2 oxygen partial pressure, µ micro, Hb haemoglobin, SO2 oxygen saturation, DO2 systemic 
oxygen transport, HPV hypoxic pulmonary vasoconstriction, MAP mean arterial pressure, SVR systemic vascular resistance, NO: nitric oxide, HIF-1α: 
hypoxia-inducible factor 1 alpha, NF-κB nuclear transcription factor kappaB, ROS reactive oxygen species, ATP adenosine triphosphate; adapted from 
Asfar et al. [16] with kind permission from Springer Science and Business Media
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temperature, arterial PO2 levels of 90–100  mmHg lead 
to hemoglobin O2 saturations close to 100 % due to the 
sigmoid shape of the hemoglobin-O2-dissociation curve. 
Therefore, pure O2 breathing will only raise the amount 
of physically dissolved O2, the maximum effect being a 
five-fold increase, while hardly modifying the amount of 
O2 bound to hemoglobin. It is self-evident from the afore-
mentioned estimate that the effect of pure O2 breathing 
on total blood O2 content will be the more important the 
lower the hemoglobin concentration. Therefore, ventila-
tion with 100 % O2 was particularly protective in various 
models comprising critical hemodilution (reviewed in 
Calzia et  al. [12]): the most impressive evidence in this 
context are the data reported in the “Live without blood” 
experiment as early as in 1960 [18]: in pigs subjected to 
hemodilution to a hematocrit <1–2  % (!), mechanical 
ventilation with pure O2 allowed preventing the other-
wise marked ECG signs of myocardial ischemia, and no 
sequelae were observed after blood re-transfusion and 
return to air breathing. Strikingly, however, despite its 
frequent routine use, so far there are no clinical data on 
the role of mechanical ventilation with FiO2 =  1.0 dur-
ing the management hemorrhagic shock, most likely due 
to ethical constraints. The available pre-clinical data are 
equivocal: deleterious and beneficial effects as well as no 
therapeutic efficacy at all were reported, depending on 
the species used, the severity of shock, and the concomi-
tant use of therapeutic hypothermia [19–25].
No matter the definitive role of pure O2 breathing dur-
ing situations of critical reductions in blood O2 transport 
capacity due to blood loss and/or hemodilution, pre-oxy-
genation, i.e., administration of 100 % O2 prior to induc-
tion of anesthesia and/or airway management, is well 
established to markedly increase the margin of safety: 
the “safe time of apnea” (i.e., the time until transcutane-
ous O2 saturation fell below 90  %) was doubled, when 
the FiO2 was increased from 60 to 100 % [26]. It must be 
noted, however, that even short-term pure O2 ventila-
tion under these conditions may be associated with for-
mation of atelectasis (see below). In healthy, non-obese 
patients with American Society of Anesthesiologists 
physical status I or II, this atelectasis formation was pre-
vented by using an FiO2 of 0.8, but the safe time of apnea 
was significantly shorter [26]. Unfortunately, there is no 
ideal FiO2, which allows achieving a maximum “safe time 
of apnea” with the least formation of atelectasis [27, 28]: 
the degree of the latter depends on the patients’ age [29], 
body mass index [30], and underlying chronic pulmonary 
co-morbidity [31].
Interestingly, this concept of a prolonged margin of 
safety seems to be valid in coronary artery disease for 
O2 breathing as a preventive, pre-treatment measure: 
breathing 15  L/min O2 prevented the recurrence of 
pacing- [32] and prolonged the time until occurrence of 
exercise-induced angina [33].
Pulmonary effects
Pure O2 breathing impairs pulmonary gas exchange as a 
result of inhibition of hypoxic pulmonary vasoconstric-
tion induced by the rise in alveolar and mixed-venous 
PO2 [34, 35]. Moreover, as already mentioned-above, 
within a few minutes, e.g., after only 5 min of apnea and 
oxygenation during induction of anesthesia [26], pure O2 
breathing causes formation of atelectasis with increased 
intrapulmonary right-to-left shunt. This “adsorption ate-
lectasis” [36, 37] is due to instability of lung regions that 
are still open but poorly ventilated in relation to perfu-
sion, so-called low ventilation/perfusion-ratio (VA/Q) 
regions [38], when the inert carrier gas N2 is washed out. 
In healthy volunteers, breathing 100  % O2 over approx. 
25  min under normobaric conditions doubled intra-
pulmonary right-to-left shunt, while breathing air at 
equal inspiratory O2 partial pressure, i.e., in a hyperbaric 
chamber pressurized to 4.9 atmospheres of ambient pres-
sure, did not affect gas exchange [12]. During induction 
of anesthesia, this atelectasis formation was prevented 
at least in part by using CPAP breathing and subsequent 
face mask ventilation with a PEEP of 6–10 cmH2O [39, 
40]. In mechanically ventilated patients with acute lung 
injury, the degree of hyperoxia-induced adsorption 
atelectasis could at least be attenuated by using higher 
PEEP levels: increasing PEEP from 5 to 14 cm H2O com-
pletely blunted the fall of the PaO2/FiO2 ratio from 200 to 
150 mm Hg induced by increasing the FiO2 from 0.6 to 
1.0 [37].
Acute hyperoxia-induced impairment of gas exchange 
must be discriminated from pulmonary O2 toxicity 
[41, 42], the so-called Lorrain-Smith effect [43] first 
described by Lavoisier in 1783 [44]. Pulmonary O2 toxic-
ity may present as severe pulmonary inflammation, ulti-
mately leading to hemorrhagic pulmonary edema, and 
is referred to excess ROS and reactive nitrogen species 
(RNS) formation [45, 46]. However, despite the abun-
dant evidence on hyperoxia-induced acute lung injury 
from studies in experimental animal (for reviews see 
[45, 47]), so far no biomarkers have been identified in 
humans that would allow evaluating the degree of ROS 
and/or RNS formation, and, moreover, thereby avoiding 
pulmonary O2 toxicity. Consequently, albeit intuitively 
being a logical therapeutic approach, there are no large 
scale data on the prevention of pulmonary O2 toxicity by 
ROS scavengers in humans, similar to the equivocal role 
of antioxidants in critically ill patients in general [48, 49]. 
In healthy experimental animals, pulmonary O2 toxic-
ity is a result of either long-term exposure and/or inju-
rious ventilator settings leading to ventilator-induced 
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lung injury (VILI) (for examples, see [50, 51]). In con-
trast, lung-protective ventilation using low tidal volumes 
with higher PEEP levels and/or titrated to the thoraco-
pulmonary compliance curve [52] over shorter periods 
had no deleterious effect at all [53], and this was also 
true during 24  h of lung-protective ventilation at FiO2 
1.0 in in large animals [25, 54]. In humans, the duration 
of pure O2 breathing needed to provoke pulmonary O2 
toxicity is unknown [55]: various studies reported that 
exposure period of 6–25 h were associated with clinical 
and histological signs of tracheitis and/or alveolitis [45, 
56, 57], whereas other authors suggested that “…direct 
oxygen toxicity only plays a negligible role in regards to 
perioperative administration..” [58] and that breathing 
an FiO2 of 0.96–1.0 for 48 h does not produce symptoms 
of toxicity in most men [45, 59]. The only data available 
from mechanically ventilated ICU patients originate 
from mechanical ventilation with FiO2 >0.85–0.9 for 
>10  days [60, 61], and FiO2 =  1.0 over 14  h to 30  days 
[62, 63], respectively. Unfortunately, the studies do not 
report ventilator settings, but, given the publication 
years (1967–1972), it is unlikely that low tidal volumes 
and high PEEP levels according to current guidelines 
were used. Two more recent studies yielded equivocal 
results: observational data from patients mechanically 
ventilated for >48 h with “excessive inspired O2” (defined 
as an “FiO2 >0.5 while maintaining SO2 >92 %” observed 
in 155 out of 210 patients during a 12-month observa-
tion period) showed significantly lower PaO2/FiO2 ratio 
and higher mean airway pressures at 48 h [64]. In con-
trast, retrospective analyses of patients after cardiac 
arrest showed that higher quartiles of the “area under 
curve of FiO2” were not associated with any effect on 
gas exchange or lung mechanics during the first 24 h of 
mechanical ventilation [65]. Nevertheless, in this study 
the highest quartile of the “area under curve of FiO2” 
coincided with decreased survival to hospital discharge 
and worse neurological outcomes. Hence, no threshold 
value for the duration of hyperoxia exposure leading to 
pulmonary O2 toxicity is known in mechanically ven-
tilated patients. Most likely, defining such a threshold 
is per se impossible: it is well known from hyperbaric 
(patho)physiology that intermittent exposure to hyper-
oxia with interspersed short periods of air breathing 
markedly attenuates pulmonary O2 toxicity when com-
pared to an equally long, but continuous exposure [66]. 
The problem of defining a threshold value for the initia-
tion of pulmonary O2 toxicity was highlighted during the 
discussion of “Oxygen” during the 50th Respiratory Care 
Journal Conference held April 13–14, 2012, in San Fran-
cisco, CA: “…oxygen toxicity is like Bigfoot: everybody’s 
heard about it, but nobody’s ever seen it…” [45].
Vascular effects
Hyperoxia decreases cardiac output, on the one hand 
due to a fall in heart rate caused by increased parasym-
pathetic tone [67], on the other hand due to a rise in sys-
temic vascular resistance [68–70]. The latter may result 
from decreased ATP release from red blood cells [71] 
and/or reduced NO bioavailability. Stamler et  al. ele-
gantly demonstrated that the hyperoxia-induced increase 
in tissue and, consequently, venous PO2 levels blocks the 
release of NO from cystein-binding in the hemoglobin-
molecule (S-nitrosothiol) [72]. In addition, increased 
ROS formation contributes to hyperoxia-induced vaso-
constriction: administration of vitamin C (200 mg intra-
arterial [69] and 3  g intra-venous [73], respectively), 
restored forearm [69] and coronary vascular resistance 
[73]. While varying among the different vascular regions, 
the degree of the hyperoxia-induced vasoconstriction 
is particularly pronounced in the cerebral and coronary 
circulation. Therefore, it was argued that this hyperoxia-
related vasoconstriction may impede tissue O2 delivery in 
patients with sepsis [74] or cardiovascular disease [75], 
but it is still a matter of debate whether the hyperoxia-
induced vasoconstriction is beneficial or deleterious: in 
fact, 30 min of pure O2 breathing impaired the sublingual 
microcirculatory perfusion by decreasing the number 
and density of perfused vessels, while it even increased 
perfusion heterogeneity [76]. It must be noted, however, 
that most of the studies available in the literature on 
hyperoxia-induced systemic or regional vasoconstriction 
were performed in healthy volunteers or at least under 
stable hemodynamic conditions, i.e., without imbalance 
between O2 supply and demand, or, during circulatory 
shock. In addition, any hyperoxia-related increase in vas-
omotor tone could possibly allow reducing vasopressor 
demands required to counteract shock-induced hypo-
tension. Finally, experimental data suggest that pure O2 
ventilation may redistribute cardiac output in favor of the 
kidney and the hepato-splanchnic system and thereby 
improve visceral organ function [25, 54, 77]. Yet, scarce 
data are only available on the effects of ventilation with 
FiO2 =  1.0 on systemic or regional hemodynamics and 
organ function in patients with circulatory shock. Only 
one prospective pilot study, including 83 patients admit-
ted to the emergency department with two or more sys-
temic inflammatory response syndrome (SIRS) criteria 
and a suspected infection, i.e., sepsis, reported no associ-
ation between in-hospital mortality and hyperoxia (FiO2 
between 0.4 and 0.8) [78], but only three patients with 
septic shock were included in total. Therefore, the results 
of the prospective, randomized, controlled HYPER2S 
(NCT01722422) trial (see Table 1) will certainly help to 
answer this question.
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Metabolic effects
No matter the definitive effect of hyperoxia on vascu-
lar tone during circulatory shock, any conclusion on 
the role of hyperoxia-induced vasoconstriction must be 
considered in the context of the effects of hyperoxia on 
metabolic activity. Clearly, in  vitro long-term (≥24  h) 
exposure to hyperoxia was associated with impaired 
mitochondrial respiratory capacity as a result of partial 
inhibition of NADH and succinate dehydrogenase, i.e., 
complex I and II [79, 80], whereas cytochrome c oxidase 
(complex IV) remained unaffected [79]. Pure O2 breath-
ing also decreased whole body O2 uptake in healthy vol-
unteers [76, 81] as well as in critically ill patients [70, 82], 
and myocardial O2 consumption in patients with coro-
nary artery disease [83]. Nevertheless, this reduced O2 
uptake more likely mirrored decreased O2 demand rather 
than impaired O2 utilization: There was no deleterious 
effect on any marker of systemic energy balance [70, 82], 
and myocardial lactate extraction was even enhanced 
[83]. Moreover, studies in experimental animals [25, 
54] and healthy volunteers [81] showed that hyperoxia 
increased the respiratory quotient to values close to 1.0, 
in other words suggesting that hyperoxia shifted energy 
metabolism to preferential utilization of carbohydrates 
[25, 54], which is well established to increase the yield of 
the mitochondrial respiratory chain [84], i.e., the molar 
ratio of O2 consumption and ATP formation [85]. Similar 
to the situation during exercise in highlanders [86], this 
effect might assume particular importance under condi-
tions of limited tissue O2 supply, e.g., hemorrhagic and/
or cardiogenic shock.
Cerebral effects
In addition to the above-mentioned pulmonary toxic-
ity, pure O2 breathing may also have toxic effects on the 
central nervous system, the so-called Paul-Bert effect 
[87], the most dramatic manifestation being general-
ized tonic–clonic (grand mal) seizures [11]. This central 
nervous toxicity, however, requires pure O2 breathing 
under supra-atmospheric pressures, i.e., during diving 
and/or in a hyperbaric chamber. Hence, only critically 
ill patients treated with hyperbaric oxygenation (HBO: 
pure O2 breathing at supra-atmospheric pressures; e.g., 
for decompression injury (DCI), gas embolism, carbon 
monoxide (CO) poisoning, and gas gangrene or necrotiz-
ing fasciitis) will present with central nervous O2 toxic-
ity-induced convulsions, which occur within approx. 
20–30 min of pure O2 exposure at ambient pressures of 
three atmospheres. Interestingly, in contrast to the cer-
ebral vasoconstriction normally observed during pure 
O2 breathing, symptoms are preceded by a paradoxi-
cal increase in cerebral blood flow velocity [88] (Fig. 2), 
Table 1 Clinical trials on the effects of hyperoxia in intensive care and emergency medicine
ICU intensive care unit, FiO2 fraction of inspired O2 concentration, SpO2 transcutaneous hemoglobin O2 saturation, PaO2 arterial O2 partial pressure, CK-MB myocardial 
creatine kinase, cTnI cardiac troponin I, TBI traumatic brain injury, GCS Glasgow Coma Score, GOS Glasgow Outcome Score, GOSE Extended Glasgow Outcome Score
Study acronym Trial no. Patient condition Intervention Primary outcome  
measures
Planned enrolment
OXYGEN-ICU NCT01319643 ICU treatment for 3 days FiO2 titrated to 
SpO2 94–98/PaO2 
70–100 mmHg vs. 
SpO2 >97 %/PaO2 
100–150 mmHg
Mortality day 30 Terminated at n = 434 
(slow recruitment)
HYPER2S NCT01722422 Septic shock FiO2 titrated to SpO2 
88–95 % vs. FiO2 = 1.0 
over the first 24 h
Mortality day 28 Terminated at n = 442
AVOID NCT01272713 Acute myocardial  
infarction
Air (unless SpO2 <94 %) 
vs. 8 L/min O2 during 
pre-hospital phase, 
thereafter according to 
hospital protocol
Infarct size, time course of 
CK-MB and cTnI
Completed at n = 638
DETO2X-AMI NCT01787110 Acute coronary syndrome Air (unless SpO2 <90 %) vs. 
6 L/min O2 over 6–12 h
Mortality at 1 year 6600
BRAINOXY NCT01201291 TBI, GCS ≤8 FiO2 0.4 vs. 0.7 GOS/GOSE at 6 months n un-specified; terminated 
(slow recruitment)
SO2S ISRCTN52416964 Stroke, ICH Air vs. 2 (SpO2 >93 %)/3 
L/min overnight vs. 2 
(SpO2 >93 %)/3 L/min 
continuously until day 3
Modified Rankin scale at 
day 90
Completed at n = 8003
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which is referred to peroxynitrite (ONOO−) formation 
resulting from the reaction of NO with the superoxide 
radical (O2−) [89], and thereby causing a dysregulation of 
the endogenous NO availability [46, 90].
Clinical application of hyperoxia
CO intoxication, gas embolism, and DCI
No matter any possible deleterious effects related to 
enhanced ROS and RNS formation, pure O2 breath-
ing is  the therapy of choice during CO intoxication, gas 
embolism, and DCI. While the beneficial effect of hyper-
oxia during CO intoxication is related to the competitive 
replacement of CO in heme moieties, the salutary role 
of O2 during DCI and/or gas embolism is due to the so-
called oxygen window effect.
Recent reports show that approx. 1  ‰ of patients 
admitted to emergency departments present with occult 
CO-intoxications [91]. CO has a several-fold higher affin-
ity to heme moieties than O2, and thus it reduces the 
blood O2 transport capacity by preventing hemoglobin 
(Hb) O2 saturation. This effect on tissue O2 transport 
is further aggravated by the leftward-shift of the Hb-
O2-dissociation curve, which impairs O2 release from 
oxy-hemoglobin [92]. Nevertheless, CO toxicity is mainly 
due to the blockade of complex IV of the mitochondrial 
respiratory chain (i.e., cytochrome c oxidase) [93]. Ulti-
mately, this inhibition of mitochondrial respiration will 
result in oxidative and nitrosative stress [94], which also 
explains that pure O2 breathing is the therapy of choice 
in patients with CO intoxication: albeit at first glance 
paradoxical, increasing the PO2 in fact reduces rather 
than further increases ROS and RNS formation during 
CO intoxication [94], because high O2 concentrations 
will restore normal electron transport within the respira-
tory chain and thereby decrease radical production. The 
half-life of CO elimination is inversely related to the arte-
rial PO2 [95], and therefore, intuitively, HBO therapy is 
indicated in patients with CO-intoxication. However, the 
results of the available RCT are equivocal [96–98], and a 
recent meta-analysis concluded that normobaric hyper-
oxia is as efficient as HBO, in part as a result of the CO 
elimination achieved with normobaric pure O2 breathing 
during patient transport to an HBO chamber [99].
By definition gas embolism is the—mostly iatrogenic—
entry of gas bubbles into the vascular system in general 
[100], whereas decompression injury (DCI) comprises 
medical disorders resulting from a decrease in ambient 
pressure (i.e., decompression) that results in intra- or 
extra-vascular bubble formation due to excess (i.e., super-
saturation) inert gas (in most cases N2) tensions [101]. 
However, DCI can also cause arterial gas embolism due 
to introduction of alveolar gas emboli via cardiac shunts 
and/or pulmonary vessels, but more frequently pre-
sents as decompression sickness (DCS), which is caused 
by excess supersaturation during and after decompres-
sion [102]. Treatment is breathing 100  % O2, and, as far 
as DCI is concerned, in combination with recompression, 
i.e., HBO [103]. In addition to its ability to improve tissue 
oxygenation and attenuate inflammation, pure O2 breath-
ing is therapy of choice because it maximizes the inert gas 
gradient from the tissues to the alveolar gas and thereby 
accelerates inert gas washout [102]. Moreover, it will 
enhance bubble resolution due to the increased inert gas 
diffusion gradient (i.e, the oxygen window) (Fig. 3 [103]).
Acute coronary syndrome
In 1940, supplemental O2 breathing was described as “…
as an efficient method of relieving the intense pain which 
may accompany acute coronary thrombosis and as an 
important therapeutic adjunct in the symptomatic con-
trol of severe angina pectoris…” [104], and subsequently 
became a cornerstone of the management of the Acute 
Coronary Syndrome. However, due to the above-men-
tioned coronary vasoconstriction [83], which was also 
more recently demonstrated to be due to NO quenching 
[105] associated with oxidative and nitrosative stress [73], 
this approach has been questioned [106, 107], despite 
data from patients with acute decompensated heart fail-
ure showing no effect of the arterial PO2 on all-cause 
mortality [108]. Therefore, the latest guidelines of the 
European Resuscitation Council on the initial manage-
ment of acute coronary syndromes recommend that an 
“…O2 saturation of 94–98  %, or 88–92  % if the patient 
Fig. 2 Original recordings of ECG and cerebral blood flow velocity 
(CBFV) in two volunteers undergoing an HBO exposure-test with pure 
O2 breathing at three atmospheres of ambient pressure. In the upper 
panel, HBO-induced seizures were preceded by tachycardia, agitation, 
and a subsequent marked increase in CBFV. The lower panel shows 
a volunteer, in whom seizures could be prevented by removing the 
O2 face mask; CBFV consecutively fell to lower levels comparable to 
those during the asymptomatic period
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is at risk of hypercapnic respiratory failure…” should be 
achieved, in other words, “…supplementary O2 should 
be given only to those patients with hypoxaemia, breath-
lessness or pulmonary congestion…” [109]. Until most 
recently, the evidence for these guidelines was surpris-
ingly scarce, because over four decades only four clinical 
trials enrolling a total of just 447 patients were published 
[110–113]. Moreover, the results of these trials were 
far from being conclusive: In 17 patients with anterior 
transmural myocardial infarction (MI), Madias et  al. 
reported reduced ischemic injury as assessed by precor-
dial ST-mapping during 48–80  min of breathing 15 L/
min O2; however, this study did not include any control 
group [110]. In 157 patients with confirmed MI, Rawles 
et al. found no difference in the incidence of arrhythmias 
and use of analgesics after 6 L/min O2 over 24 h vs. air 
breathing; however, mortality in the O2-group tended to 
be higher without reaching statistical significance (3.9 vs. 
11.3 %, p = 0.08) [111]. More recently, in a total of 137 
patients using two different protocols for supplemental 
O2, Ukholkina et al. demonstrated that a FiO2 of 0.3–0.4 
until 3  h after interventional myocardial revasculariza-
tion decreased the number of early post-intervention 
arrhythmia, which was associated with lower peak values 
of myocardial creatine kinase activity, and, ultimately, 
smaller relative area of ischemic damage. However, 37 % 
of the patients had baseline O2 saturations <94  %, i.e., 
below the threshold recommended for initiating sup-
plemental O2 administration. Moreover, for reasons 
unexplained, time to revascularization was longer in the 
O2-group [112]. Finally, Ranchord et al. found “…no evi-
dence of benefit or harm…” from high-concentration (6 
L/min O2 over 6  h) vs. titrated O2 therapy (to achieve 
O2 saturations of 93–96 %) in 136 patients with initially 
uncomplicated ST-elevation myocardial infarction [113]. 
Therefore, as highlighted in recent reviews [106, 107], 
there is urgent need for large clinical trials assessing 
whether or not O2 therapy should be used for the man-
agement of acute coronary syndrome, and the results of 
the DETO2X-AMI (NCT01787110) (see Table  1) trial 
Fig. 3 Effect of increased oxygen partial pressure on bubble size. After creation of a concentration gradient (1), oxygen starts to diffuse into the 
bubble, simultaneously nitrogen diffuses out of the bubble (2). Thereby, oxygen molecules are now capable of passing the bubble with concomi-
tant reduction of nitrogen concentration (3). Finally, the bubble size decreases significantly (4). Adapted from Muth et al. [103] with kind permission 
from Springer Science and Business Media
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is to answer this question. The most recently completed 
AVOID (NCT01272713) (see Table  1) trial has partly 
answered this need: in non-hypoxaemic (transcutane-
ous hemoglobin O2 saturation >94 %) patients with ST-
elevation myocardial infarction (n = 441), high flow face 
mask O2 (8  L/min) up to 4  h after percutaneous coro-
nary intervention increased myocardial injury, recurrent 
infarction, major cardiac arrhythmia, and late (6 months) 
myocardial infarct size. Mortality at hospital discharge 
did not significantly differ (p  =  0.11), but interestingly, 
was 2.5 fold higher in the normoxia group. At 6 months, 
however, both overall (hyperoxia: 3.8, normoxia: 5.9  %; 
p  =  0.32) and cardiac (hyperoxia: 2.9, normoxia 4.1  %) 
mortality were comparable [114].
Traumatic and ischemic brain injury
From a pathophysiological point of view, any hyperoxia-
induced vasoconstriction could theoretically represent an 
interesting approach in the management of brain injury, 
inasmuch as it would allow reducing intracranial pressure 
(ICP) and thereby improving cerebral perfusion pressure 
without impairment of O2 supply. Clearly, HBO (60 min 
of mechanical ventilation with pure O2 at 1.5 atmospheres 
of ambient pressure was shown to efficiently decrease 
ICP in patients with traumatic brain injury (TBI) [115]. 
Combining HBO with subsequent normobaric hyperoxia 
even improved long-term outcome: at 6  months mor-
tality was reduced (9 out of 22 vs. 3 out of 20 patients, 
p =  0.048), and overall neurological outcome was more 
favorable as evaluated with the sliding dichotomized 
Glasgow Outcome Score (8 out of 21 vs. 14 out of 19 
patients, p =  0.024) [116]. However, normobaric hyper-
oxia alone yielded equivocal results with respect to tissue 
oxygenation and metabolism as assessed by microdialysis 
[117–122], which was referred to a lacking effect on brain 
tissue oxygenation in hypo-perfused regions [120] and/
or a possibly enhanced hyperoxia-related excitotoxicity 
[122]. Albeit there is some data available using magnetic 
resonance imaging (MRI), suggesting that hyperoxia may 
have a beneficial effect in the peri-lesional penumbra 
[123], the role of hyperoxia in TBI is still controversially 
discussed because of the equivocal outcome data [124]: 
while a uni-variate analysis found a significant associa-
tion between hyperoxemia (arterial PO2 >100  mmHg) 
and a decreased risk of 6-month mortality in a retrospec-
tive analysis of 1116 patients, the corresponding multi-
variate logistic regression adjusted for illness severity 
did not show any significant relationship [125]. How-
ever, Davis and co-workers showed in a large retrospec-
tive cohort analysis including 3420 patients that both 
hypoxemia (PaO2  <  110  mmHg) and extreme hyperox-
emia (PaO2 > 487 mmHg) were associated with increased 
mortality and unfavorable outcome among TBI patients 
[126]. Moreover, two other retrospective studies analyz-
ing a total of 1759 patients using multi-variate approaches 
showed that hyperoxemia defined as arterial PO2 >200 or 
>300  mmHg, respectively, was independently associated 
with increased mortality [127, 128]. These data are in con-
trast to another retrospective study, reporting that oxygen 
partial pressures between 250 and 486 mm Hg were asso-
ciated with improved all-cause survival in patients with 
severe TBI [129]. So far, the answer to the question of the 
use of hyperoxia in TBI is still pending: the BRAINOXY 
study (NCT01201291), which was to answer this ques-
tion, was terminated due to slow recruitment.
The currently available data on hyperoxia (with con-
secutive hyperoxemia) during ischemic brain injury, 
i.e., stroke and/or intracranial bleeding, is less conflict-
ing: Albeit there is compelling experimental evidence 
(for review, see [130]) and some encouraging pilot data 
in patients [131, 132], evidence from large trials suggests 
that hyperox(em)ia is deleterious. A prospective, single-
center observational study in 252 patients showed that 
hyperoxemia (as defined as a PaO2 >173  mmHg) was 
associated with delayed cerebral ischemia and, conse-
quently, poor neurological outcome [133]. In addition, a 
more recent retrospective analysis of 2894 mechanically 
ventilated patients with ischemic stroke, subarachnoid 
or intracerebral hemorrhage demonstrated that more 
pronounced hyperoxemia (arterial PO2 >300  mmHg) 
significantly increased in-hospital mortality at day 28 
[134]. In contrast, a retrospective analysis of 2,643 adults, 
ventilated for ischemic stroke in ICUs in Australia and 
New Zealand, showed no apparent relationship between 
mortality and PaO2 levels during the first 24  h in ICU 
[135]. Finally, the Normobaric Oxygen Therapy in Acute 
Ischemic Stroke Trial (NCT00414726), which was to 
study the effects of high-flow O2 (30–45 L/min for 8 h via 
facemask) was terminated prematurely after enrolment 
of 85 of 240 patients due to imbalance in deaths favoring 
the control arm (hyperoxia: 17 out of 43 patients, room 
air: 7 out of 42 patients, p = 0.03). The question, however, 
whether hyperoxia is definitely deleterious, remained 
unanswered: deaths were not attributed to treatment 
by the blinded external medical monitor. No matter the 
impact of high-flow supplemental O2, even low-dose O2 
administration (2 L/min either continuously over 72 h or 
over-night only) only targeted to compensate for mild, in 
particular nocturnal, hypoxemia (Stroke Oxygen Study, 
SO2S; ISRCTN52416964) did not improve outcome after 
ischemic stroke: despite promising pilot data in 289 
patients at 1 week and 6 months [136, 137], the complete, 
full-scale study in 8003 patients did not show any differ-
ence in morbidity (disability at day 90 as assessed by the 
modified Rankin Scale) or mortality (data presented at the 
XXIII European Stroke Conference, Nice, May 7, 2014).
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Cardiac arrest
The pronounced vasoconstrictor effect in the cerebral 
circulation together with the potential to aggravate oxi-
dative stress during ischemia/reperfusion have prompted 
investigations on the association between hyperox(em)
ia and outcome after cardiopulmonary resuscitation. So 
far only retrospective analyses are available, except for 
one randomized controlled single centre trial including 
28 patients in total, the results being again fairly equivo-
cal: a multicenter cohort study on 6326 patients con-
cluded that hyperoxemia defined as PaO2 >300  mmHg 
was associated with higher mortality than normoxemia 
and even hypoxemia defined as PaO2 <60 mmHg) [138]. 
A secondary analysis of 4459 patients of this study even 
yielded a direct linear relationship between PaO2 incre-
ments and increased risk of mortality, a PaO2 increment 
of 100 mmHg being associated with a 24 % higher odds 
ratio for unfavorable outcome [139]. Another retrospec-
tive analysis of 12,108 patients found no association 
between PaO2 deciles or hyperoxemia defined as PaO2 
>309  mmHg and mortality adjusted for illness sever-
ity [140]. Other authors analyzing smaller data bases 
confirmed this latter finding [141, 142]. Clearly, dif-
ferent temperature management (lowest temperature: 
median 34.9  °C in [140] vs. mean 36  °C in [138]; 33 vs. 
6 % of patients <34 °C) in the various countries may have 
contributed to these divergent findings, albeit a single-
center, retrospective analysis of 170 patients treated 
with therapeutic hypothermia (12–24 h at 32–34 °C core 
temperature) showed that mortality and poor neurologi-
cal outcome were more frequent in patients with higher 
maximum PaO2 values (median 254 vs. 198  mmHg) 
during the first 24 h after cardiac arrest [143]. This is in 
line with another retrospective analysis in 213 patients 
after cardiac arrest, treated with therapeutic hypother-
mia, demonstrating a U-shaped independent association 
between the mean PaO2 and poor neurologic outcome at 
hospital discharge [144]. The sole randomized controlled 
trial, comparing 14 patients in each group ventilated with 
either 30 or 100 % oxygen for 1 h after return of spontane-
ous circulation (ROSC), showed increased levels of neu-
ron specific enolase in the hyperoxic group at 24 h post 
cardiac arrest [145]. Unfortunately, this study was not 
powered to analyze outcome parameters. Finally, other 
smaller studies focusing on the role of arterial PCO2 
did not yield any deleterious effect of hyperoxemia per 
se on neurological outcome [146–148]. Consequently, a 
recent meta-analysis concluded that hyperoxemia (PaO2 
>300 mmHg) “…appears to be correlated with increased 
in-hospital mortality…”, which, however, “…should be 
interpreted cautiously because of the significant hetero-
geneity…of studies analyzed…” [149]. Lately, two more 
interesting retrospective cohort analyses reported that 
severe hyperoxia was associated with decreased survival 
as well as decreased survival and worse neurological out-
come, respectively [65, 150]. Nelskylä et al. offer an inter-
esting explanation for the vast majority of retrospective 
studies being in favor of normoxia: In their retrospective 
analysis of 119 out of hospital cardiac arrest patients, 
hyperoxia occurred more frequently in association with 
out-of-hospital cardiac arrest, longer times to ROSC, and 
delays to ICU admission, i.e., the patients with the worst 
prognosis per se [142]. In addition, safe titration of oxy-
gen therapy to achieve a SpO2 of 90–94  % after out-of-
hospital cardiac arrest might not be feasible, at least in 
the pre-hospital period [151]. Taken together, all these 
studies demonstrate the urgent need for data from pro-
spective, randomized controlled trials, and the ongoing 
REOX trial (NCT01881243) will at least help to answer 
this demand.
Peri‑operative hyperoxia
The use of intra-operative (and, in a broader sense, peri-
operative) hyperoxia to prevent surgical site infection 
does not directly refer to the treatment of circulatory 
shock and medical emergencies, but patho-physiological 
effects of hyperoxemia also assume importance in this 
context. The antimicrobial properties of oxygen are due to 
the bactericidal properties associated with increased ROS 
production, and were already recognized in the 1980s 
(“oxygen as an antibiotic” [152]), subsequently prompt-
ing several clinical studies which have so far enrolled 
more than 5000 patients. Recent meta-analyses of these 
studies concluded that high inspired O2 concentrations 
values (FiO2 = 0.8 vs. 0.3 as the standard approach) dur-
ing the peri-operative period reduced the risk of surgical 
site infection, both after elective and emergency sur-
gery, without leading to major post-operative atelectasis 
[153, 154]. This protective effect was specifically present 
in non-obese patients undergoing colo-rectal surgery, 
one possible component being a better patency of anas-
tomoses [155]. The molecular mechanisms of hyper-
oxia-related reduction in surgical site infection remain 
unclear: hyperoxic ventilation was reported to restore 
the local inflammatory response to normal—rather than 
leading to potentially deleterious hyper-inflammation—
thereby improving the antimicrobial potential of alveolar 
macrophages [156]. However, other authors found that 
ex  vivo exposure to hyperoxia not only enhanced ROS 
formation but even decreased the capacity of endotoxin-
stimulated leukocytes to release tumor necrosis factor-α 
[157]. It is noteworthy that despite this short-term (up 
to 2  weeks within surgery) benefit, high intra-operative 
FiO2 was associated with higher long-term (>2  years) 
post-operative mortality. This observation was nearly 
exclusively due to a higher mortilaty in patients that had 
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undergone cancer surgery [158], and coincided with a 
significantly shorter cancer-free survival interval [159]. 
Therefore, and taking into account the trials showing no 
benefit for surgical site infection after abdominal surgery 
[160, 161], the most recent Cochrane analysis concluded 
that “…evidence is insufficient to support the routine use 
of a high fraction of inspired O2 during anesthesia and 
surgery….” [162].
What is the optimal PaO2 for ICU survival?
So far, this question remains unanswered as well: a retro-
spective analysis of arterial PO2 measurements in 36,307 
patients during the first 24  h of ICU stay demonstrated 
a U-shaped relationship of in-hospital mortality, the 
nadir of the mortality curve (as calculated from the logis-
tic regression with the PaO2 incorporated using a spline 
function) being at values of 15–20 kPa (110–150 mmHg); 
mortality sharply increased both at PaO2 values <9 
(67 mmHg) and >30 kPa (225 mmHg) [163]. Interestingly, 
this group of authors recently showed a similar U-shaped 
relation between arterial PCO2 and PO2, respectively, 
and hospital mortality after cardiac arrest, the high-
est probability of survival being associated with a PaO2 
values of 180–200  mmHg, i.e., most likely with an FiO2 
>0.6 in a substantial number of patients [164]. A more 
recent study of unadjusted odds ratios for PaO2 deciles 
in 152,680 patients confirmed the impact of hypoxemia, 
whereas hyperoxemia even >40 kPa (300 mmHg) had no 
impact on outcome [165]. Finally, a retrospective cohort 
study including 83,060 patients after cardiac surgery 
showed that there was no association between mortal-
ity and hyperoxia in the first 24  h in ICU after cardiac 
surgery [166]. Therefore, two recent meta analyses con-
cluded that hyperoxia may be associated with increased 
mortality in patients with stroke, TBI, and post cardiac 
arrest and with poor hospital outcome, respectively [167, 
168]. However, due to heterogeneity of the included stud-
ies, the authors state that more evidence is needed to pro-
vide optimal oxygen targets for critical care physicians. 
The results of the OXYGEN-ICU (NCT01319643) trial 
(see Table  1) will certainly contribute to the answer of 
this question. Interestingly, most ICU clinicians acknowl-
edge the potential adverse effects of prolonged exposure 
to hyperoxia, however, in actual clinical practice, a large 
proportion of their patients was exposed to higher arte-
rial oxygen levels than self-reported target ranges [169].
Conclusion
Hyperoxia (i.e., ventilation with a FiO2 = 1.0) is a corner-
stone of the acute management of circulatory shock, a con-
cept which is based on compelling experimental evidence 
that compensating the imbalance between O2 supply and 
requirements (i.e., the oxygen dept) is crucial for survival, 
at least after trauma [170, 171]. On the other hand oxygen 
toxicity due to the increased formation of ROS limits its 
use, because it may cause serious deleterious side effects, 
especially in conditions of ischemia/reperfusion. While 
these effects are particularly pronounced during long-term 
administration, i.e., beyond 12–24 h, several retrospective 
studies suggest that even hyperoxemia of shorter duration 
is also associated with increased mortality and morbidity. 
In fact, albeit the clinical evidence from prospective stud-
ies is surprisingly scarce, a recent meta-analysis suggests 
that hyperoxia is associated with increased mortality at 
least in patients after cardiac arrest, stroke and TBI [172]. 
Most of these data, however, originate from heterogenous, 
observational studies with inconsistent results, and there-
fore, there is a need for the results from the large scale, 
randomized, controlled clinical trials on the use of hyper-
oxia, which can be anticipated within the next 2–3 years. 
Consequently, until then, “…conservative…” O2 therapy 
[140] represents the treatment of choice to avoid exposure 
to both hypoxemia and excess hyperoxemia.
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